Optima Health Plc · LSE:OPT
Optima Health — FY2025 Earnings Presentation
22 slides from Optima Health's earnings presentation, Jul 8, 2025
Slide 1: FY25 – Full Year Results
FY25 – Full Year Results 8th July 2025
Slide 2: Agenda
Agenda FY25 Financial Headlines 01 Jonathan Thomas Strategic Progress & Outlook 02 Jonathan Thomas Jonathan Thomas Chief Executive Officer Financial Review 03 Heidi Giles Q&A 04 Open Q&A session Heidi Giles Chief Financial Officer 2 11/07/2025 Optima Health | Commercial in Confidence
Slide 3: Optima Health PLC
Optima Health PLC 3 11/07/2025 Optima Health | Commercial in Confidence
Slide 4: Significant Long-Term Growth Potential within Core Market
Significant Long-Term Growth Potential within Core Market At a Glance Growth Drivers £1.2bn – UK OH Market Combined economic cost of ill- health absence / presenteeism in £150bn the UK (186m days – 5.7 per Favourable population dynamics worker) 3% 14% Forecast growth of UK OH Increased corporate foc
Slide 5: FY25 Financial Headlines
FY25 Financial Headlines Jonathan Thomas 5 11/07/2025 Optima Health | Commercial in Confidence
Slide 6: FY25 Financial Headlines
FY25 Financial Headlines FY25: £105.0m (FY24: £110.9m) FY25: £17.6m (FY24: £18.0m) Adjusted Revenue Contraction due to previously disclosed contract loss and a scope reduction in Q3FY24. Adjusted underlying organic EBITDA1 Inline with reduced revenue in period. growth 4.1% . FY25: £27.2m (FY24: £7.3
Slide 7: Strategic Outlook & Progress
Strategic Outlook & Progress Jonathan Thomas 7 11/07/2025 Optima Health | Commercial in Confidence
Slide 8: Strategic Outlook: Growth Strategy Targets 25% Market Share and Expansion
Strategic Outlook Growth Strategy: Targets 25% Market Share and Expansion Beyond Core Market Core market organic growth Strategic fundamentals Extension into new markets and track record M&A to accelerate growth Areas of focus Track record and tested Strong Market Dynamics Consolidation bolt-ons – l
Slide 9: Post Listing - Strategic Progress
Post Listing - Strategic Progress UK Consolidation Acquired February 25 – Integration commenced £7.5m Revenues (OH Business) Access to ROI market Acquired April 25 – Collaboration opportunities €7m Revenues Mental Health bolt on Acquired May 25 – Integration commenced £3.7m Revenues In use by 5 trus
Slide 10: Growth and Operational Initiatives
Growth and Operational Initiatives Growth Operational • Transformational contract win delivering medicals to UK Armed • Transition of UK Armed Forces Contract Underway – service Forces in partnership with Serco revenues commencing in around 18 months time – 7-year initial term with options up to 10
Slide 11: Financial Review
Financial Review Heidi Giles 11 11/07/2025 Optima Health | Commercial in Confidence
Slide 12: Financials – Statement of Comprehensive Income
Financials – Statement of Comprehensive Income Statement of Comprehensive Income FY25 FY24 £m £m • Resilient performance against decreased revenue in FY25 Revenue 105.0 110.9 – Cost of sales reduced Cost of sales (72.0) (74.4) – Administrative expenses reduced Gross profit 33.0 36.5 – Adjusted EBITD
Slide 13: Revenue Reconciliation
Revenue Reconciliation Rev enue Reconciliation FY25 FY24 £m £m • Underlying Revenue – Underlying revenue removes the second-year impact of the Reported Revenue 105.0 110.9 -5.3% client who descoped their services from October 2023 and the Client A lost at tender - 3.2 client we lost at tender who ex
Slide 14: Exceptional Costs
Exceptional Costs Exceptional costs in FY 2025 of £3.9 million No restructuring/integration costs expected in FY 2026 • Integration Costs £1.1 million: • All costs relating to the demerger from Marlowe – the final costs relating to the integration of the legacy PLC and the AIM listing were incurred
Slide 15: Financials – Statement of Financial Position
Financials – Statement of Financial Position Statement of Financial Position 31-Mar-25 31-Mar-24 £m £m • Strengthened balance sheet Non-Current Assets 184.1 184.6 – Net Assets at 31st March 2025 £168.1m compared to £127.6m at 31st Inventories 0.1 0.1 March 2024. Trade and other receivables 19.2 17.5
Slide 16: Financials – Cashflow and Net Debt
Financials – Cashflow and Net Debt CASH FLOW and NET DEBT FY25 • Net cash generated from operations £m – Improved by £5.3m compared to £0.1m at H1 FY25 Adjusted EBITDA 17.6 • Working capital movement Restructuring, demerger and listing costs (4.2) Working Capital movement (7.9) – £3.8m reduction in
Slide 17: Investment Highlights
Investment Highlights 17 11/07/2025 Optima Health | Commercial in Confidence
Slide 18: Investment Highlights
Investment Highlights UK leader by size in corporate health and wellbeing sector serving public and private sectors Large and growing market with attractive dynamics Profitable, contracted and recurring revenue model FY26 growth and confidence in outlook - plus multiple drivers of long-term growth,
Slide 19: Q&A
Q&A 19 11/07/2025 Optima Health | Commercial in Confidence
Slide 20: Appendix
Appendix 20 11/07/2025 Optima Health | Commercial in Confidence
Slide 21: Technical Guidance
Technical Guidance • Exceptional costs – No integration costs expected to be recognised FY26 Guidance – Small amount of external advice costs for acquisitions completed to date, and some end of employment costs Exceptional costs: Integation activity nil – Share based accounting required under IFRS2
Slide 22: Slide 22